AADI,"{'Contentsour', 'LLC', 'Aadi Bioscience', 'Physician Payments Sunshine Act', 'Condensed Consolidated Statements of Operations and Comprehensive LossRevenueProduct Sales', 'Mirati Therapeutics, Inc. (&', 'Contractual Obligations', 'Aerpio Pharmaceuticals', 'Hedging &#8211', 'Contracts with Customers (&#', 'The BMS License Agreement', 'Aerpio 32Table of Contentsimmediately', 'EMA', 'non-European Union', 'Restricted Stock Unit Award Agreement', 'ContentsOther', 'this Quarterly Report on Form 10-Q', 'Bioscience, Inc. 2023', 'FYARRO', 'ActivitiesOur', 'Principal Executive Officer Pursuant', 'BioScience', 'BMS License AgreementWe', 'the Sarbanes-Oxley Act of', 'NSCLC', 'FDA&#8217;s Oncology Center of Excellence', 'ProceduresUnder', 'SOX', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'Aspen Merger Subsidiary, Inc.', 'NOL', 'NetOther', 'COVID-19', 'Principal Financial Officer Pursuant', 'the Aadi Bioscience', 'the Pacific Palisades Lease', 'FASB', 'Hong Kong Special Administration Region', 'Anti-Kickback Statute', 'EOC Pharma', 'Medicaid', 'Medicare', 'Congress', 'the Securities and Exchange Commission', 'the EOC License Agreement', 'The Gossamer License Agreement', 'GDPR', 'ContentsComparison', 'FDA', 'the CVR Agreement', 'the Federal Deposit Insurance Corporation', 'ContentsThe', 'Risks Related', 'HIPAA', 'REMS', 'Silicon Valley Bank', 'Company', 'USPTO', 'Adopted Pursuant to Section 302', 'Concentration of Credit RiskFinancial', 'Cowen', 'PartiesWe', 'the Delaware General Corporation Law', 'ContentsThere', 'ASU', 'Significant Accounting Policies Basis of PresentationThe', 'CMS', 'BMS', 'Celgene Corporation', '2023).10.2#Executive Employment Agreement', 'License AgreementsBristol Myers Squibb Company License AgreementOn', 'Gossamer Bio, Inc.', 'FCPA', 'the U.S. Department of Health and Human Services', 'NetOur', 'Aadi Bioscience, Inc.', 'the International Chamber of Commerce&#8217;s International Court of Arbitration', 'Contentscommon', 'Bristol Myers Squibb Company', 'Aadi Subsidiary, Inc.', 'the Children&#8217;s Health Insurance Program', 'NDA', 'Share-Based Compensation The Company', 'ContentsOur', 'the Fresenius Agreement', 'DOJ', 'TSC1 &amp', 'NetFYARRO', 'the Sarbanes-Oxley Act', 'the General Data Protection Regulation', 'us;&#8226;a', 'the EOC Territory', 'PGR', 'Cowen and Company', 'Form S-3', 'treasury', 'the Form S-3', 'the BMS License Agreement', 'this Quarterly Report', 'Contracts', 'Bristol Myers Squibb Company (&#8220;BMS&#8221', 'FDA&#8217;s', 'the &#8220;Shelf Registration', 'European Union', 'U.S. Securities and Exchange Commission', 'the Federal Food, Drug and Cosmetic Act', 'LDTs', 'Medicaid Services', 'Pre-Funded Warrants', 'November&#160;8', 'Healthcare', 'United', 'SEC', 'the Shelf Registration Statement', 'Administrative ExpensesSelling', 'The EOC License Agreement', 'the Gossamer License Agreement', 'EOC', 'ContentsPatent', 'the Centers for Medicare &', 'ASC Topic', 'the European Union'}"
ABCL,"{'Bruker Cellular', 'Schrader', 'OverviewWe', 'the University of British Columbia', 'Form S-3', 'RevenueThe', 'BCBCA', 'Critical Accounting Policies', 'this Quarterly Report', 'the International Data Transfer Agreement and International Data', 'Adopted Pursuant to Section 906', 'Dayhu JV Loan', 'XBRL Taxonomy Extension Definition', 'the U.S. Internal Revenue Service', 'the &', 'FCPA', 'InformationDuring', 'this Quarterly Report on Form 10-Q to &#8220;AbCellera,&#8221', 'the EU Commission', 'the Governments of Canada', 'EEA', 'this Quarterly Report on Form 10-Q', 'GDPR', 'Strategic Innovation Fund', ': &', 'Passive Foreign Investment Company', 'Lilly', 'EU', 'FDA', 'the &#', 'the Interactive Data File', 'Dayhu Investments', 'GMP', ': &#', 'Principal Executive Officer Pursuant', 'Court', 'AbCellera Biologics Inc.', 'Percent Shareholders', 'the Government of Canada', 'the Sarbanes-Oxley Act of', 'Columbia) Ltd.', 'Bruker Cellular Analysis', 'Upfront', 'the Coronavirus Treatment Acceleration Program', 'U.S. Treasury Regulations', 'Registrant', 'HIPAA', 'Delaware General Corporation Law', 'September&#160;30', 'SEC', 'the Minister of Industry', 'SIF', 'Company', 'the Securities Exchange Act', 'the Strategic Innovation Fund', 'Item 408 of', 'September&#160;30, 2023', 'the Government of British Columbia', 'COVID-19', 'Regulation S-K).72Item 6', 'Adopted Pursuant to Section 302', 'Biologics Inc.', 'Principal Financial Officer Pursuant', 'the Sarbanes-Oxley Act', 'Eli Lilly and Company', 'CapitalAccumulated', 'F', 'the California Consumer Privacy Act', 'the Ministry of Jobs, Economic Development and Innovation'}"
ABEO,
ABIO,"{'API', 'Treasury Regulations', 'Good Laboratory Practices', 'The Funicular Fund', 'HF', 'U.S. Department of Justice', 'the Nasdaq Capital Market; &#x2022;general', 'EEA', 'EU', 'GCP;\\n  &#x2022;unforeseen', 'Indicate', 'care;\\n  &#x2022;Reduction', 'and\\n  &#x2022;an', 'the University Medical Center Mainz', 'COVID-19', 'Swiss-U.S. Privacy Shield', '\\n  &#x2022;the board', 'or\\n  &#x2022;on', 'and\\n  &#x2022;the FDA', 'x2022;a court', 'x2022;if', 'Recent Accounting PronouncementsThe Company', 'EF &#x2265', 'Medicaid', 'Medicare', '\\n  &#x2022;general', 'all;\\n  &#x2022;long', 'FDA', '\\n  &#x2022;collaborations', 'and\\n  &#', 'the World Health Organization', ': &#x2022;the', 'Scientific', 'Company', 'GLP', 'the Nasdaq Capital Market', 'operations;\\n  &#', 'CCPA', '\\n  &#x2022;the', 'the Sales Agreement', 'LabCorp', '\\n  &#x2022;infringement', 'AF', 'Cable Car Capital', '\\n  &#', 'Our Business and Financial Condition \\n', '\\n  &#x2022;collaborators', 'NDA', 'the Center for Thrombosis and Hemostasis', '\\n  &#x2022;our', 'Form S-3', 'Phase', 'operations;\\n  &#x2022;spend', 'bradycardia;\\n  &#x2022;Reduction', '\\n  &#x2022;pursue', 'SPA', 'health care &#', 'Good Clinical Practices', '\\n  &#x2022;delays', 'ROU', 'ARCA', 'x2022;refuse', 'AF;\\n  &#x2022;One', 'products;\\n  &#x2022;seize', 'us;\\n  &#x2022;suspend', '\\n  &#x2022;obtain', 'treatment;\\n  &#x2022;difficulty', 'CTH', 'Medtronic', 'products;\\n  &#x2022;assume', '\\n  &#x2022;successfully', 'the University of Colorado', 'the University Medical Center of Johannes', 'GCP', 'prosecutions;\\n  &#x2022;close', 'letters;\\n  &#x2022;suspend', 'or\\n  &#x2022;merge', 'Item 408 of Regulation S-K. \\n', 'the European Union-U.S.'}"
ABOS,"{'agreements$1,534&#160;$1,077&#160;Prepaid insurance1,216&#160;1,106&#160;Dues', 'Condensed Financial Statements', 'BofA Securities, Inc.', 'LLC', 'CRO', 'Company, Incorporated', 'Form S-3', 'the Wall Street Journal', 'the Loan Agreement', 'this Quarterly Report on Form 10-Q.', 'Loan Agreement', 'Ankura Trust Company', 'the SEC.29Table of ContentsItem 6', 'ATM', 'the Securities and Exchange Commission', 'Development ExpensesResearch', ': &', 'Company, Incorporated (&#8220;Stifel&#8221', 'Halozyme, Inc. (&#8220;Halozyme&#8221;).Under', 'ContentsAcumen Pharmaceuticals', 'Lonza Sales AG', 'ContentsOperating Activities Net', 'BofA Securities, Inc. (&#8220;BofA&#8221', 'the Public Company Accounting Oversight Board', 'ACU193', 'Loan', 'Lenders', 'Indicate', 'the Halozyme License Agreement', 'Stifel, Nicolaus &amp', 'SEC', 'Common Stock', 'Company', 'Financial Information', 'Restated Certificate of Incorporation', 'Halozyme, Inc.', 'the Securities Exchange Act', 'Swiss Francs', 'the Prime Rate', 'the heading &#8220;Special Note Regarding Forward-Looking', 'November&#160;1', 'Halozyme', 'IPO', 'November&#160;10', 'Restated Bylaws', ': &#8226;the', 'the Registration Statement'}"
ABSI,"{'LLC', 'Cowen and Company', 'Form S-3', 'TrademarksThis Quarterly Report on Form 10-Q', 'this Quarterly Report', 'The Shelf Registration Statement', 'this Quarterly Report on Form 10-Q.', 'CLD Active Programs', 'the Securities and Exchange Commission', 'PhaseBio', 'the U.S. Food and Drug Administration', 'FDA', 'the Public Company Accounting Oversight Board', 'all Active Programs', 'Change% ChangeRevenuesTechnology development revenue$5,380&#160;$3,094&#160;$2,286&#160;74&#160;%Collaboration', 'this Quarterly Report on Form 10-Q to &#8220;Absci,&#8221', 'the Form S-1', 'development$35,798&#160;$47,593&#160;$(11,795)(25)%Selling', 'the Sarbanes-Oxley Act of', 'Registrant', 'OperationsThe', 'Form S-1', 'Goodwill', 'SEC', 'the Shelf Registration Statement', 'Integrated Drug Creation', 'Absci Corporation', 'Company', 'Change% ChangeRevenuesTechnology development revenue$744&#160;$2,004&#160;$(1,260)(63)%Collaboration', 'the Securities Exchange Act', 'Cumulative', 'SFJ Pharmaceuticals, Inc.', 'the Sarbanes-Oxley Act', 'Equity Securities', 'IPO', 'Capital', 'netGoodwill'}"
ABUS,"{'ASC', 'MaximumMember2023', 'RNA', 'OMERS.Genevant Sciences, Ltd.', 'NA', 'EMA', 'AssemblyBiosciencesIncMember2023-01-012023-09-300001447028abus', 'Financial Instruments', 'Jefferies LLC', 'OtherMilestoneandRoyaltyPaymentsMember2023', 'FairValueInputsLevel1Member2022-12-310001447028us-gaap', 'X-Chem', 'the &#', 'Acuitas', 'DEL', 'AssemblyBiosciencesIncMember2022-07-012022-09-300001447028abus', 'the Cross-License Agreement', 'liabilities&#8212;&#160;6&#160;Total', 'Genevant Sciences Ltd.', 'Court', 'NonCashRoyaltyMember2022-01-012022-09-3000014470282023-07-012023-09-3000014470282022-07-012022-09-3000014470282022-01-012022-09-30iso4217:USDxbrli:', 'Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;).ONPATTRO', 'ArbutusPlansMember2022-07-012022-09-300001447028abus', 'The Company and Assembly', 'the Financial Accounting Standards Board', 'X-Chem, Inc. (&', 'COVID-19', 'Acuitas Therapeutics, Inc. (', 'the Share Purchase Agreement', 'loss$(19,520)$(18,474)(51,933)(50,193)See', 'the LNP License Agreement', 'Roivant Sciences Ltd.', 'USTreasuryBillSecuritiesMember2023', 'QiluPharmaceuticalCoLTDMember2021', 'InvestmentsInMarketableSecuritiesNoncurrentMemberabus', 'the Open Market Sale Agreement3,832,717&#160;8,973&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;8,973&#160;Issuance', 'NonCashRoyaltyMember2022', 'Alnylam', 'ONPATTROGlobalNetSalesMember2023-01-012023-09-300001447028abus', 'CommonStockMemberabus', 'ArbutusInc', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'the Securities and Exchange Commission', 'OMERS', 'LNP', 'FDA', 'Oct2020RegistrationStmtMember2023-10-220001447028us-gaap', 'Prospectus Supplement', 'Alnylam LNP', 'InvestmentsInMarketableSecuritiesCurrentMember2023-09-300001447028abus', 'InvestmentsInMarketableSecuritiesNoncurrentMember2022-12-310001447028abus', 'the Ontario Municipal Employees Retirement System', 'the American Society of Clinical Oncology', 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR', 'Company', 'SharesShare', 'LicenseMember2023-01-012023-09-300001447028abus', 'nsp5', 'Assembly', 'AssemblyBiosciencesIncMember2023-07-012023-09-300001447028abus', 'Arbutus Biopharma, Inc.', 'Purchase Agreement', 'OVERVIEWArbutus Biopharma Corporation', 'X-Chem, Inc.', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001447028us-gaap', 'October2021ProspectusSupplementMemberabus', 'ArbutusPlansMember2022-01-012022-09-300001447028us-gaap', 'HBV', 'CandidatesOur', 'the Sale Agreement', 'Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221', 'USCorporateBondsMember2023', 'Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221', 'Peg-IFN&#945;-2a', 'Proteros', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001447028us-gaap', 'USTreasuryBillSecuritiesMember2022-12-310001447028abus', 'MinimumMemberabus', 'MaximumMemberabus', 'ONPATTRO', 'FairValueMeasurementsRecurringMember2023', 'Qilu Pharmaceutical Co., Ltd.', 'QiluPharmaceuticalCoLTDMember2021-12-130001447028abus', 'Member2014-10-310001447028us', 'the Open Market Sale', 'Inc.$714&#160;$1,256&#160;$2,980&#160;$4,339&#160;Qilu Pharmaceutical Co.', 'AssemblyBiosciencesIncMember2022-01-012022-09-300001447028abus', 'Form S-3', 'the License Agreement', 'Acuitas Therapeutics Inc.', 'Contracts with Customers (&', '2022.The Company', 'Arbutus', 'Arbutus Biopharma Corporation', 'VaccitechMember2022', 'LicenseMember2023-07-012023-09-300001447028abus', 'Arbutus Inc.', 'Columbia', 'compensationThe', 'ArbutusPlansMember2023-01-012023-09-300001447028abus', 'Financial Instruments - Credit Losses', 'the U.S. District Court', 'SEC', 'NonCashRoyaltyMember2023', 'ArbutusPlansMember2023-07-012023-09-300001447028abus', 'GenevantSciencesCorporationMember2023-01-012023-09-300001447028srt', 'agreementsCollaborationsQilu Pharmaceutical Co., Ltd.', 'the District Court of New Jersey', 'ONPATTROGlobalNetSalesMember2014-01-012014-', 'ASC Topic', 'the Securities and Exchange Commission &', 'LicenseMemberabus'}"
ABVC,"{'ASC', 'API', 'LLC', 'the Collaborative Agreement', 'warrants\\nto', 'the BioFirst Collaborative Agreement', 'BioFirst', 'ABV-1601', 'ABVC', 'Euro-Asia Investment &', 'the Lind Securities Purchase Agreement,\\nthe Note', 'Transaction', 'NSCLC', '\\n    Research', 'the Co-Dev Agreement', 'Form S-1', 'Operations &', 'the BHK Agreement', 'Co-Development', 'Principal Executive', 'BioLite', 'the Securities Exchange Act', 'Thalia Media Ltd.', 'Securities Purchase Agreement', 'the Agreement.\\n\\n&#160;\\n\\nThe Company', 'MDD', 'ADHD (Attention Deficit\\nHyperactivity Disorder', 'COVID-19', 'CNS', 'the Co-Dev Agreement\\nwas', 'Unaudited)&#160;&#160;\\n    &', 'Company&#8217;s\\nentry', 'Holdings', 'The Common Stock', 'LLC (&#8220;Allele&#8221', 'profit&#160;\\n    &', 'Company\\nalso', 'the ticker symbol &#', 'Critical Accounting', 'the Securities and Exchange Commission', 'ABV-2001 Intraocular Irrigation Solution\\nand ABV-2002 Corneal Storage Solution', 'the Current Report on Form 8-K', 'Rgene&#8217;s Common Stock', 'the Company (See Note 8)', 'Principal Financial', 'FDA', 'Company&#8217;s\\ncommon', 'AIBL', 'Lucidaim Co., Ltd.', 'Non-Small Cell Lung', 'the securities of &#8220;penny', 'GMP', 'the Licensed Products', 'ABVC BioPharma, Inc.', 'Restated American BriVision (Holding) Corporation', 'BioPharma', 'collaboration\\npartners.\\n\\n&#160;&#160;\\n\\nAs\\npart', 'Company\\nare', 'the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'the Note and Loan Agreement', 'the Rgene Agreement', 'Central Nervous Systems', 'Co-Dev Agreement', 'Barlew Holdings', 'Non-Small Cell Lung Cancer', 'Biolite JP', 'Common Stock', 'the BioFirst Collaborative Agreement\\nwas', 'Company', 'the Nasdaq Listing\\nQualifications Department', 'BioLite BVI', 'the Cathay United Loan', 'Shareholders', 'Internal Control over', 'BioKey, Inc.', 'Report', 'income&#160;\\n    &', 'Joint Venture Agreement', 'the Service Agreement', 'Financial Reporting\\n\\n&#160;\\n\\nThere\\nhas', 'ASU', 'the Original Registration Statement,\\nthe &#8220;Registration', 'the Nasdaq Capital Market', 'the &#8220;Placement', 'BioLite Japan', 'the Quarterly Report on Form 10-Q', 'the Company receives.\\n\\n&#160;\\n\\nCollaborative\\nRevenues &#', 'Stock Purchase Agreement (&', 'Grantor', 'Purchase / Exchange', 'Plant and Equipment (&', 'IND/NDA', 'the Intellectual Property\\nOffice', 'Chengdu) Group Co., Ltd.', 'Report.\\n\\n&#160;\\n\\nThere\\nare', 'Articles of Incorporation', 'The Loan Agreement', 'TCD', 'the U.S. FDA IND', 'K.K.', 'Common Stock and ii', 'RGC', 'tax&#160;\\n    &', 'BioKey', 'Wilmington Capital Securities', 'The Financial Industry\\nRegulatory Authority (&#8220;FINRA&#8221', 'BriVision', 'the BioLite Agreement', 'Lind Global Fund II', 'BioLite Taiwan\\nhas', 'the BHK Co-Development Agreement', 'the Transaction Documents', 'Registrant', 'the Mandatory Default Amount', 'NDA', 'Inverlew Advisors', 'channels.\\n\\n&#160;\\n\\nBusiness\\nObjectives\\n\\n&#160;\\n\\nThe\\nCompany', 'Cathay Bank', 'The BHK Co-Development Agreement', 'a Patent Security Agreement', 'BioLite Taiwan', 'BioFirst Collaborative', 'Zhonghui United Technology', 'NT$31,649,000', 'BioFirst granted\\nthe Company', 'BioLite, Inc. (&#8220;BioLite&#8221', 'Property', 'BioLite Inc.', 'the Cathay United Loan Agreement', 'which\\nthe Mandatory Default Amount', 'the Lind Offering', 'Form S-3', 'a\\nClinical Development Service Agreement', 'Bank', 'the Loan Agreement', 'Board', 'Oncology/ Hematology', 'SPA', 'BioLite JP', 'schedule:\\n\\n&#160;\\n\\n  &#160', 'the BioFirst Agreement', 'Lucidaim', 'YuanGene Corporation', 'Finance', 'the Lind Securities Purchase Agreement', 'LionGeneCorporationtheLionGeneMember\\n    \\n', 'Purchase Agreement 2', 'the obligations\\nof the Company', 'BioFirst in\\na', 'Incorporation of the Company', 'the &#8220;Reserved', 'American BriVision Corporation', 'BHK Co-Development', 'Lind', 'JP', 'BioFirst\\n(Australia', 'CTBC Bank', 'Accounting Standards Codification', 'Securities Purchase Agreement&#160;(27)\\n', 'Ophthalmology, Oncology', 'share:&#160;\\n    &', 'BHK Co-Development\\nAgreement', 'SEC', 'upfront\\npayments\\n\\n&#160;\\n\\nIf\\na', 'Zhonghui United Technology\\n(Chengdu) Group Co., Ltd.', 'U.S. FDA IND', 'the Board of Directors of the Company', 'compensation&#160;\\n    &', 'American BriVision (Holding) Corporation', 'BHK', 'recognition.\\n\\n&#160;\\n\\n(i', '\\n    &', 'the Loan Agreement and Note'}"
ABVX,